An Open Label, 7-day Repeat Dose Study to Evaluate the Pharmacodynamics of SB-656933-AAA in Patients With Ulcerative Colitis.
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Elubrixin (Primary)
- Indications Ulcerative colitis
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 07 Jun 2017 Biomarkers information updated
- 16 Mar 2012 Actual end date changed from 1 Oct 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.
- 16 Mar 2012 Actual end date (1 Oct 2009) added as reported by EudraCT.